Akira Kurokawa - Santen Pharmaceutical CEO

  CEO
Mr. Akira Kurokawa was serving as Chairman of the Board, Chief Executive Officer and Representative Director in Santen Pharmaceutical Co., Ltd. since April 1, 2018. He joined the Company in April 1977. His previous titles include Director of Pharmaceutical Business, Executive Officer, Managing Executive Officer and Chief Operating Officer in the Company. He used to serve as President and Director in a subsidiary, Santen Holdings U.S. Inc.
Age: 65  CEO Since 2018      
81 6 6321 7000  http://www.santen.com

Management Efficiency

The company has return on total asset (ROA) of 7.23 % which means that it generated profit of $7.23 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 11.01 % meaning that it generated $11.01 on every $100 dollars invested by stockholders.

Entity Summary

Santen Pharmaceutical Co., Ltd. researches and develops, produces, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market.Santen Pharmaceutical Co Ltd (SNPHY) is traded on OTC Market in USA and employs 3,805 people.

Santen Pharmaceutical Leadership Team

Satoshi Suzuki, Executive Officer, Chief Director of Planning
Kanoko Ohishi, Independent Director
Noriaki Yamamoto, CIO, Head of Information Systems Division and Corporate Officer
Akira Kurokawa, CEO and President Director, Member of Nominating Committee, Member of Executive Compensation Committee and Member of Corporate Strategy Committee
Hidetaka Mizutani, Manager of Finance & Accounting Group
Kenji Morishima, Executive Officer, Chief Director of Human Resources & Organization Development and CSR
Sadatoshi Furukado, Senior Managing Executive Officer, Director of Medical Business, Director
Ken Araki, Executive Officer, Senior Director of Global Business Development
Masamichi Sato, Head of CSR and General Affairs Division and Sr. Corporate Officer of Corporate Devel.
Kazuo Koshiji, CFO, Head of Fin. Division and Sr. Corporate Officer
Akihiro Tsujimura, Executive Officer, Director of Asia Business
Takeshi Ito, Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit
Frank Binder, Executive Officer, Chief Director of Supply Chain
Yutaro Shintaku, Independent Director
Akihiro Okumura, Independent Director
Yutaro Shinta, Independent Director
Jyrki Liljeroos, Executive Officer and Presidentident of Subsidiary
Shiro Hatagami, Manager of Finance & Accounting Group
Keizo Nakada, Executive Officer, Chief Director of Product Supply
Ko Takahashi, Executive Officer
Akio Kimura, Executive Officer, Chief Director of Reliability Guarantee
Miki Fujima, Executive Officer, Chief Director of Human Resources
Naveed Shams, Chief Scientific Officer, Executive Officer and Presidentident and CEO of Subsidiary
Atsutoshi Ohta, Executive Officer, Chief Director of Production & Logistics
Hiroyuki Yamazaki, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit
Takahiro Morita, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit
Ye Liu, Executive Officer, General Manager of Subsidiary
Takayuki Katayama, Independent Director
Luis Iglesias, Executive Officer
Shigeo Taniuchi, Executive Officer and Presidentident of Subsidiary
Kunihito Minakawa, Independent Director

Stock Performance Indicators

Current Sentiment - SNPHY

Santen Pharmaceutical Investor Sentiment

Macroaxis portfolio users are evenly split in their outlook on investing in Santen Pharmaceutical Co Ltd. What is your outlook on investing in Santen Pharmaceutical Co Ltd? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip
Currently Active Assets on Macroaxis
GOOG   
Purchased few shares of
3 hours ago
Traded for 1103.6
S   
Purchased over 400 shares of
3 hours ago
Traded for 7.23
CRM   
Purchased a lot of shares of
3 hours ago
Traded for 150.59
GE   
Purchased over 200 shares of
3 hours ago
Traded for 10.42
F   
Purchased over 300 shares of
3 hours ago
Traded for 10.1
Also please take a look at World Market Map. Please also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Search macroaxis.com